Which stocks are gapping on Friday?
By Mill Chart
Last update: Apr 26, 2024
Let's have a look at the gap up and gap down stocks in today's session.
Gap up stocks
| Ticker | Change | Comment |
|---|---|---|
| ATXI | 6.0K% | AVENUE THERAPEUTICS INC's (NASDAQ:ATXI) shares rose 6.0K% to $7.48 with a gap of 6.0K% during Friday's session. Shareholders saw the stock price going 23.33% lower in the past month. |
| ZVSA | 687.0% | Exciting news for ZYVERSA THERAPEUTICS INC's (NASDAQ:ZVSA) stock! It advanced 687.0% to $4.8 in today's session, accompanied by a notable 630.0% gap. In the last month the stock lost 21.87%. |
| BDRX | 69.97% | In today's session, BIODEXA PHARMACEUTICALS-ADR's (NASDAQ:BDRX) stock experienced a notable rise of 69.97%, reaching $1.22 with a remarkable gap of 63.51%. The stock is trading 62.05% lower than 3 months ago. |
| PEGY | 58.19% | PINEAPPLE ENERGY INC's (NASDAQ:PEGY) shares soared 58.19% to $0.08 in Friday's session, displaying an impressive 42.78% gap. In the last 3 months the stock lost 89.82%. |
| EXPO | 24.66% | EXPONENT INC's (NASDAQ:EXPO) shares surged 24.66% to $99.33 with a remarkable gap of 13.8%. A press release (Exponent Declares Regular Quarterly Dividend for Q2 2024) was released yesterday. |
| SNAP | 24.03% | In today's session, SNAP INC - A's (NYSE:SNAP) stock experienced a notable rise of 24.03%, reaching $14.14 with a remarkable gap of 19.36%. A press release (Snap Inc. Announces First Quarter 2024 Financial Results) was released yesterday. |
| TPC | 23.18% | In today's session, TUTOR PERINI CORP's (NYSE:TPC) stock experienced a notable rise of 23.18%, reaching $17.11 with a significant 12.62% gap. A press release (Tutor Perini Reports First Quarter 2024 Results) was released yesterday. |
| SLCA | 19.95% | US SILICA HOLDINGS INC's (NYSE:SLCA) shares rose 19.95% to $15.66 with a gap of 18.17% during Friday's session. yesterday the company released their earnings. |
| RERE | 18.94% | Exciting news for ATRENEW INC's (NYSE:RERE) stock! It advanced 18.94% to $1.92 in today's session, accompanied by a substantial gap of 4.32%. Shareholders saw the stock price going 30.89% higher in the past 3 months. |
| ZIM | 18.35% | ZIM INTEGRATED SHIPPING SERV's (NYSE:ZIM) shares soared 18.35% to $13.48 during Friday's session, accompanied by a significant gap of 3.48%. Shareholders saw the stock price going 39.93% higher is the past 6 months. |
Our gap up stocks screener will show you the full list.
ZYVERSA THERAPEUTICS INC
NASDAQ:ZVSA (5/17/2024, 7:00:03 PM)
After market: 4.48 -0.01 (-0.16%)4.4872
-0.37 (-7.67%)
ZVSA News
2 days ago - InvestorPlaceZVSA Stock Earnings: ZyVersa Therapeutics Misses EPS for Q1 2024ZVSA stock results show that ZyVersa Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
2 days ago - BusinessInsiderZVSA Stock Earnings: ZyVersa Therapeutics Misses EPS for Q1 2024InvestorPlace - Stock Market News, Stock Advice & Trading Tips ZyVersa Therapeutics (NASDAQ:ZVSA) just reported results for the first quarter ...
3 days ago - ZyVersa TherapeuticsZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business UpdateZyVersa is on track to achieve key development milestones over the next 3 quarters....
4 days ago - ZyVersa TherapeuticsZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International ConventionTo learn more about ZyVersa's Inflammasome ASC Inhibitor and Renal Pipelines, schedule a one-on-one meeting on 2024 BIO International Conference's Portal....
19 days ago - ZyVersa TherapeuticsZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s DiseaseNLRP1 & pyrin govern inflammation in Alzheimer’s Disease, and release of inflammasome laden extracellular vesicles induces cardiovascular inflammation....
a month ago - ZyVersa TherapeuticsZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with DiabetesInhibiting inflammasome pathways has potential to attenuate atherosclerosis in patients with diabetes, a leading cause of morbidity & mortality....
2 months ago - ZyVersa TherapeuticsZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateKey Highlights:
